Search
Sufentanil
go.drugbank.com/drugs/DB00708ApprovedInvestigationalSufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. … Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately [L4718].
Synonyms: N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide, N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilideBetibeglogene autotemcel
go.drugbank.com/drugs/DB16900ApprovedInvestigational[L42940] BB305 LVV encodes β<sup>A-T87Q</sup>-globin, compensating for the lack of β-globin in these patients. … [A251770] Allogeneic hematopoietic-cell transplantation would be a therapeutic option in patients with β-thalassemia; however, this process is reserved for young children with an HLA-identical sibling
Synonyms: Autologous CD34+ cells encoding βA-T87Q-Globin geneApomorphine
go.drugbank.com/drugs/DB00714ApprovedInvestigational[A203618] Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders. … Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884.
Categories: Drugs Used in Erectile Dysfunction, Heterocyclic Compounds with 4 or More RingsProducts: APO-GO PEN 10 MG/ML, Apo-go Pen 10 mg/ml - InjektionslösungTrifarotene
go.drugbank.com/drugs/DB12808ApprovedInvestigationalTrifarotene is a topical retinoid cream used in the treatment of acne vulgaris that was first approved for use in the United States in October 2019. … to vitamin A and are analogous only in function.
Categories: Retinoids for Topical Use in Acne, Anti-Acne Preparations for Topical UsePemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigational[A193716] In April 2020, pemigatinib was approved by the FDA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously treated adult patients with a fibroblast … [A193719] FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast
Gefapixant
go.drugbank.com/drugs/DB15097Approved[L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601] … It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications.
Atogepant
go.drugbank.com/drugs/DB16098ApprovedInvestigationalnovel in that it is the first and only oral CGRP antagonist approved for preventative use in migraine. … [A239094] The "gepants" family of drugs, including atogepant, are comparatively well-tolerated[A189207,L38739] and may provide a desirable treatment option for patients struggling with adverse reactions
Icosapent
go.drugbank.com/drugs/DB00159ApprovedInvestigationalNutraceuticalImportant polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. … A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane
Mixtures: ASPEN NUTRITION PRO OMEGA 3, Live-well™ Toco-E CapsuleZalcitabine
go.drugbank.com/drugs/DB00943ApprovedWithdrawnA dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. … This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseRegdanvimab
go.drugbank.com/drugs/DB16405ApprovedWithdrawnTrials investigating the use of regdanvimab as a therapeutic candidate for the treatment of COVID-19 began in mid-2020. … [A235830,A241995] It received its first full approval in South Korea in September 2021,[A241995] followed by the EU in November 2021.[L39130]
Categories: Antiinfectives for Systemic Use, Approved Treatments for COVID-19